Real-world Data Reveal Long Drug Survival for Guselkumab in Patients with Plaque Psoriasis
DOI:
https://doi.org/10.2340/actadv.v102.685Keywords:
Psoriasis, Biologics, Drug Survival, Guselkumab, Effectiveness, SafetyAbstract
Abstract is missing (Short communication)
Downloads
References
Reich K, Griffiths CEM, Gordon KB, Papp KA, Song M, Randazzo B, et al. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: results from the VOYAGE 1 and VOYAGE 2 trials. J Am Acad Dermatol 2020; 82: 936-945.
https://doi.org/10.1016/j.jaad.2019.11.040 DOI: https://doi.org/10.1016/j.jaad.2019.11.040
Reich K, Papp KA, Armstrong AW, Wasfi Y, Li S, Shen YK, et al. Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies. Br J Dermatol 2019; 180: 1039-1049.
https://doi.org/10.1111/bjd.17454 DOI: https://doi.org/10.1111/bjd.17454
Mason KJ, Barker J, Smith CH, Hampton PJ, Lunt M, McElhone K, et al. Comparison of drug discontinuation, effectiveness, and safety between clinical trial eligible and ineligible patients in BADBIR. JAMA Dermatol 2018; 154: 581-588.
https://doi.org/10.1001/jamadermatol.2018.0183 DOI: https://doi.org/10.1001/jamadermatol.2018.0183
Lin PT, Wang SH, Chi CC. Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence. Sci Rep 2018; 8: 16068.
https://doi.org/10.1038/s41598-018-34293-y DOI: https://doi.org/10.1038/s41598-018-34293-y
Schwensen JFB, Nielsen VW, Nissen CV, Sand C, Gniadecki R, Thomsen SF. Effectiveness and safety of guselkumab in 50 patients with moderate to severe plaque psoriasis who had previously been treated with other biologics: a retrospective real-world evidence study. J Eur Acad Dermatol Venereol 2021; 35: e341-e343.
https://doi.org/10.1111/jdv.17092 DOI: https://doi.org/10.1111/jdv.17092
Iznardo H, Vilarrasa E, López-Ferrer A, Puig L. Real world drug survival of guselkumab, ixekizumab and secukinumab for psoriasis. Br J Dermatol 2021; 185: 660-662.
https://doi.org/10.1111/bjd.20416 DOI: https://doi.org/10.1111/bjd.20416
Lee EB, Reynolds KA, Pithadia DJ, Egeberg A, Wu JJ. Drug survival of guselkumab for psoriasis in a real-world setting: a single-center retrospective chart review. J Dermatolog Treat 2020; 31: 342-343.
https://doi.org/10.1080/09546634.2019.1605133 DOI: https://doi.org/10.1080/09546634.2019.1605133
Dapavo P, Siliquini N, Mastorino L, Avallone G, Merli M, Agostini A, et al. Efficacy, safety and drug survival of IL-23, IL-17 and TNF-alpha inhibitors for psoriasis treatment: a retrospective study. J Dermatolog Treat 2022; 33: 2352-2357.
https://doi.org/10.1080/09546634.2021.1961998 DOI: https://doi.org/10.1080/09546634.2021.1961998
Ruiz-Villaverde R, Rodriguez-Fernandez-Freire L, Armario-Hita JC, Pérez-Gil A, Galán-Gutiérrez M. Guselkumab: mid-term effectiveness, drug survival, and safety in real clinical practice. Dermatol Ther 2021; 34: e14798.
https://doi.org/10.1111/dth.14798 DOI: https://doi.org/10.1111/dth.14798
Torres T, Puig L, Vender R, Lynde C, Piaserico S, Carrascosa JM, et al. Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for psoriasis treatment: a retrospective multi-country, multicentric cohort study. Am J Clin Dermatol 2021; 22: 567-579.
https://doi.org/10.1007/s40257-021-00598-4 DOI: https://doi.org/10.1007/s40257-021-00598-4
Lytvyn Y, Zaaroura H, Mufti A, AlAbdulrazzaq S, Yeung J. Drug survival of guselkumab in patients with plaque psoriasis: a 2 year retrospective, multicenter study. JAAD Int 2021; 4: 49-51.
https://doi.org/10.1016/j.jdin.2021.05.003 DOI: https://doi.org/10.1016/j.jdin.2021.05.003
van der Schoot LS, van den Reek J, Grine L, Schots L, Kievit W, Lambert JLW, et al. Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study-the BeNeBio study. Trials 2021; 22: 707.
https://doi.org/10.1186/s13063-021-05681-z DOI: https://doi.org/10.1186/s13063-021-05681-z
Eyerich K, Weisenseel P, Pinter A, Schäkel K, Asadullah K, Wegner S, et al. IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE). BMJ Open 2021; 11: e049822.
https://doi.org/10.1136/bmjopen-2021-049822 DOI: https://doi.org/10.1136/bmjopen-2021-049822
Mourad A, Straube S, Armijo-Olivo S, Gniadecki R. Factors predicting persistence of biologic drugs in psoriasis: a systematic review and meta-analysis. Br J Dermatol 2019; 181: 450-458.
https://doi.org/10.1111/bjd.17738 DOI: https://doi.org/10.1111/bjd.17738
Enos CW, Ramos VL, McLean RR, Lin TC, Foster N, Dube B, et al. Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6 months: a prospective analysis in Corrona Psoriasis Registry. J Am Acad Dermatol 2022; 86: 68-76.
https://doi.org/10.1016/j.jaad.2021.06.883 DOI: https://doi.org/10.1016/j.jaad.2021.06.883
Additional Files
Published
How to Cite
License
Copyright (c) 2022 Marloes E. van Muijen, Sarah E. Thomas, Douwe Vellinga, Silke Bouwman, Martijn B.A. van Doorn, Klaziena Politiek, Marisol E. Otero, Juul M.P.A. van den Reek, Elke M.G.J. de Jong
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
